Osteonecrosis of the Jaw and the Role of Bisphosphonates: A Critical Review

American Journal of Medicine

Volumn 122, Issue 2 SUPPL., 2009, Pages

  Silverman, Stuart L ^a   Landesberg, Regina ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Bisphosphonate treatment; Intravenous bisphosphonate; Osteonecrosis of the jaw; Osteoporosis; Paget disease

Indexed keywords

ALENDRONIC ACID; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD CLOTTING DISORDER; BONE METASTASIS; BONE TURNOVER; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE CLASSIFICATION; FACE MALFORMATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAW OSTEONECROSIS; MEDICAL LITERATURE; MEDICAL RECORD REVIEW; MEDICAL RESEARCH; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOPHYSIOLOGY; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; SURGEON; SYSTEMATIC REVIEW; TOOTH INJURY;

BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; JAW DISEASES; OSTEONECROSIS;

EID: 58949085856     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.12.005     Document Type: Article

References (60)

1. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1118
2. Migliorati C.A. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21 (2003) 4253-4234
3. Ruggiero S.L., Mehrotra B., Rosenberg T., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
4. Marx R.E., Sawatari Y., Fortin M., and Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
5. American Association of Endodontists. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws [AAE Position Statement]. http://www.tupeloendo.com/pdfs/Bisphosphonate-Associated-Osteonecrosis.pdf Accessed July 10, 2008
6. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 137 (2006) 1144-1150
7. American Academy of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws. http://www.aaoms.org/docs/position_papers/osteonecrosis.pdf Accessed December 11, 2006
8. Khosla S., Burr D., Cauley J., et al., American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 (2007) 1479-1491
9. Sambrook P., Olver I., and Goss A. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Phys 35 (2006) 801-803
10. American College of Rheumatology. Bisphosphonate-associated osteonecrosis of the jaw [ACR Hotline]. Atlanta, GA: American College of Rheumatology; June 1, 2006. http://www.rheumatology.org/publications/hotline/0606onj.asp Accessed March 12, 2008
11. Ruggiero S.L., Gralow J., Marx R.E., et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2 (2006) 7-14
12. Marx R.E., Cillo Jr. J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65 (2007) 2397-2410
13. de Papp AE, Kagan R, Buinewicz A, et al. Reference range for bone turnover markers in healthy premenopausal women: a comparison of oral contraceptive users and non-users. Presented at the 27th Annual Meeting of the ASBMR; 2005; Nashville, Tennessee. Abstract SU158.
14. Hansen T., Kunkel M., Weber A., and Kirkpatrick C.J. Osteonecrosis of the jaws in patients treated with bisphosphonates: histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35 (2006) 155-160
15. Hansen T., Kunkel M., Kirkpatrick C.J., and Weber A. Actinomycosis in infected osteoradionecrosis: underestimated?. Hum Pathol 37 (2006) 61-67
16. Lugassy G., Shaham R., Nemets A., et al. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 117 (2004) 440-441
17. Cunha B.A. Osteomyelitis in elderly patients. Clin Infect Dis 35 (2002) 287-293
18. Støre G., Eribe E.R.K., and Olsen I. DNA-DNA hybridization demonstrates multiple bacteria in osteoradionecrosis. Int J Oral Maxillofac Surg 34 (2005) 193-196
19. Russo T.A. Agents of actinomycosis. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and Practice of Infectious Diseases. 4th ed. (1995), Churchill Livingstone, New York 2280-2288
20. Nair S.P., Meghji S., Wilson M., Reddi K., White P., and Henderson B. Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun 64 (1996) 2371-2380
21. Woo S.-B., Hellstein J.W., and Kalmar J.R. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753-761
22. Carter G.D., and Goss A.N. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 48 (2003) 268
23. Durie B.G.M., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates [letter]. N Engl J Med 353 (2005) 99
24. Shane E., Goldring S., Christakos S., et al. Osteonecrosis of the jaw: more research needed [editorial]. J Bone Miner Res 21 (2006) 1503-1505
25. Black D.M., Delmas P.D., Eastell R., and HORIZON Pivotal Fracture Trial Group. Once-yearly zoledronic acid 5 mg for treatment of postmenopausal osteoporosis. N Engl J Med 356 (2007) 1809-1822
26. Grbic J.T., Landesberg R., Lin S.-Q., and Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial Research Group. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial. J Am Dent Assoc 139 (2008) 32-40
27. Hoff A.O., Toth B.B., Altundag K., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23 (2008) 826-836
28. Murad O, Arora S, Farag A, Guber H. Bisphosphonates and osteonecrosis of the jaw: a retrospective study. Presented at ENDO 2006: The Endocrine Society's 88th Annual Meeting; June 24-27, 2006; Boston, Massachusetts. Abstract P2-500.
29. Cartsos V.M., Zhu S., and Zavras A.I. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc 139 (2008) 23-30
30. Felsenberg D., Hoffmeister B., Amling M., et al. Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Dtsch Arztebl 103 (2006) 3078-3081
31. Rizzoli R., Burlet N., Cahall D., et al. Impact of osteonecrosis of the jaw on osteoporosis management: executive summary of an ESCEO and Foundation for Research on Osteoporosis and Other Bone Diseases Working Group Meeting. Aging Health 6 (2007) 731-734
32. Mavrokokki A., Cheng A., Stein B., and Goss A.N. The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65 (2007) 415-423
33. Reid I.R., Bolland M.J., and Grey A.B. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone 41 (2007) 318-320
34. Landesberg R., Cozin M., Cremers S., et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66 (2008) 839-847
35. de Groen P.C., Lubbe D.F., Hirsch L.J., et al. Esophagitis associated with the use of alendronate. N Engl J Med 335 (1996) 1016-1021
36. Twiss I.M., de Water R., den Hartigh J., et al. Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J Pharm Sci 83 (1994) 699-703
37. Twiss I.M., Pas O., Ramp-Koopmanschap W., et al. The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium. J Bone Miner Res 14 (1999) 784-791
38. Wallace J.L., Dicay M., McKnight W., et al. N-bisphosphonates cause gastric epithelial injury independent of effects on the microcirculation. Aliment Pharmacol Ther 13 (1999) 1675-1682
39. Suri S., Mönkkönen J., Taskinen M., et al. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 29 (2001) 336-343
40. Leyvraz S., Hess U., Flesch G., et al. Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst 84 (1992) 788-792
41. King L.E., and Vieth R. Extraction and measurement of pamidronate from bone samples using automated pre-column derivatization, high-performance liquid chromatography and fluorescence detection. J Chromatogr B Biomed Appl 678 (1996) 325-330
42. Hoggarth C.R., Bennett R., and Daley-Yates P.T. The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse. Calcif Tissue Int 49 (1991) 416-420
43. Chapurlat R.D., Arlot M., Burt-Pichat B., et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 22 (2007) 1502-1509
44. Stepan J.J., Burr D.B., Pavo I., et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 41 (2007) 378-385
45. Black D., Schwartz A., Ensrud K., et al. A 5-year randomized trial of the long-term efficacy and safety of alendronate: the FIT Long-term Extension (FLEX) [abstract]. J Bone Miner Res 19 suppl 1 (2004) S45
46. Bone H.G., Hosking D., Devogelaer J.-P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004) 1189-1199
47. Borah B., Dufresne T.E., Chmielewski P.A., et al. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34 (2004) 736-746
48. Chavassieux P.M., Arlot M.E., Reda C., et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100 (1997) 1475-1480
49. Recker R., Masarachia P., Santora A., et al. Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin 21 (2005) 185-194
50. Recker R., Ensrud K., Diem S., et al. Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women [abstract]. J Bone Miner Res 19 suppl 1 (2004) S45
51. Borah B., Dufresne T.E., Ritman E.L., et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 39 (2006) 345-352
52. Eriksen E.F., Melsen F., Sod E., et al. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31 (2002) 620-625
53. Devogelaer J.P., Burckhardt P., Meunier P., et al. ZOL safety and efficacy over 5 years in post-menopausal osteoporosis. Osteoporosis Int 17 suppl 1 (2006) S14-S15 Abstract OC40
54. Rodan G., Reszka A., Golub E., and Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 20 (2004) 1291-1300
55. Nishii T., Sugano N., Miki H., et al. Does alendronate prevent collapse in osteonecrosis of the femoral head?. Clin Orthop Relat Res 443 (2006) 273-279
56. Lai K.A., Shen W.J., Yang C.Y., et al. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis: a randomized clinical study. J Bone Joint Surg Am 87 (2005) 2155-2159
57. Agarwala S., Jain D., Joshi V.R., and Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip: a prospective open-label study [published correction appears in Rheumatology (Oxford). 2005;44:569]. Rheumatology (Oxford) 44 (2005) 352-359
58. Fournier P., Boissier S., Filleur S., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62 (2002) 6538-6544
59. Wood J., Bonjean K., Ruetz S., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharm Exp Ther 302 (2002) 1055-1061
60. Assouline-Dayan Y., Chang C., Greenspan A., et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32 (2002) 94-124